With Solea®, Convergent has a unique opportunity to elevate the dental experience for both patients and practitioners while also enabling better clinical and business outcomes.
WALTHAM, Mass. (PRWEB)
June 01, 2023
Convergent Dental, the power behind the Solea® All-Tissue Dental Laser, today announced that Peter J. Valenti III will join the company’s Board of Directors effective June 1. Mr. Valenti has extensive leadership experience within the healthcare space, including senior roles with Hologic, Bausch + Lomb, Covidien, and Johnson & Johnson. Mr. Valenti will replace Len Hedge, who has served on Convergent Dental’s Board of Directors for the past 10 years.
“We thank Len for his guidance and his contributions to Convergent Dental’s growth and operational excellence during his tenure on the Board,” said Will Cowen, Chairman of the Board and General Partner at LRV Health. “And we welcome Pete, who brings a wealth of knowledge and experience that will be invaluable as we drive the broad-based adoption of Solea.”
Mr. Valenti is an active board member in the private equity space, as well as an executive coach. Prior to his retirement from corporate business, he focused on business turnarounds and revenue accelerations. These roles, starting with the most recent, include President and Executive Officer for Hologic’s Breast & Skeletal Health division; Bausch + Lomb Corporate Vice President and Global President, Vision Care; as well as North America President for Bausch + Lomb. Before joining Bausch + Lomb, Mr. Valenti was Vice President and General Manager, U.S. Surgical Devices for Covidien.
“With Solea®, Convergent has a unique opportunity to elevate the dental experience for both patients and practitioners while also enabling better clinical and business outcomes,” said Mr. Valenti. “I am excited to lend my strategic expertise and insights to help guide and accelerate Convergent’s growth.”
About Convergent Dental
Convergent Dental, Inc. is a privately owned dental equipment and technology company. The Company’s flagship product, Solea®, is the only CO2 laser to be cleared by the FDA for all-tissue indications and delivers an anesthesia-free, blood-free, suture-free experience that dentists can rely on. Solea® is a true breakthrough in dental laser technology that offers a completely different experience for both dentists and patients when compared to traditional instruments or any earlier laser treatment. Solea® enables increased new patient flow, better clinical outcomes, significant efficiency gains, and new procedures. Follow the company Instagram, Facebook, and LinkedIn.
Share article on social media or email: